Welcome to our dedicated page for Spruce Biosciences SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spruce Biosciences filings document the regulatory, financing and governance record of a late-stage biopharmaceutical company developing TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB). Form 8-K disclosures cover material agreements, including loan and security arrangements, at-the-market equity sale agreements, collaboration and license matters, and furnished clinical data updates related to the TA-ERT program.
Proxy materials describe shareholder voting matters, director elections, board committee changes, executive compensation and equity incentive plan matters. The filing record also includes capital-structure disclosures tied to common stock, equity awards, financing arrangements, risk factors and public-company governance.
Spruce Biosciences director Daniel K. Spiegelman received a grant of stock options for 1,700 shares of Common Stock. The options have an exercise price of 52.7000 per share and expire on May 20, 2036. Following this grant, he holds 1,700 derivative securities directly.
The options vest on the first anniversary of the grant date, with full vesting no later than the company’s 2027 annual stockholder meeting, subject to his continuous service under the 2020 Equity Incentive Plan. The award will also vest in full upon a Change in Control as defined in that plan.
Spruce Biosciences director Camilla V. Simpson received a grant of stock options covering 1,700 shares of common stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036. They generally vest on the first anniversary of the grant or by the company’s 2027 annual stockholder meeting, subject to continuous service, with full vesting upon a Change in Control.
SPRUCE BIOSCIENCES, INC. Executive Chairman Michael G. Grey received a grant of stock options covering 1,700 shares of common stock at an exercise price of $52.70 per share. These options vest on the first anniversary of the grant date, will in any case be fully vested by the company’s 2027 annual stockholder meeting, and vest in full upon a Change in Control, all subject to his continuous service under the 2020 Equity Incentive Plan.
Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.
The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.
Spruce Biosciences director Keli Walbert received a new stock option grant. The Form 4 shows an award of 1,700 stock options for common stock at an exercise price of $52.70 per share, with 1,700 derivative securities held after the transaction.
The options vest on the first anniversary of the grant date and will in any case be fully vested by the company’s 2027 annual stockholder meeting, subject to continuous service. They also vest in full upon a change in control. This is a compensation-related grant, not an open-market purchase or sale.
Spruce Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026 in virtual format. As of the March 24, 2026 record date, 1,372,278 common shares were outstanding, and 903,893 shares, or about 65.86%, were represented, establishing a quorum.
Stockholders elected three Class III directors—Michael Grey, Camilla V. Simpson and Javier Szwarcberg—to serve until the 2029 annual meeting. They also ratified BDO USA, P.C. as independent auditor for the year ending December 31, 2026 and approved, on an advisory basis, the compensation of named executive officers.
In addition, stockholders indicated a preference for holding an advisory vote on executive compensation every year. The company plans to include an annual, non-binding say‑on‑pay vote in its proxy materials until the next required frequency vote, which must occur no later than the 2032 annual meeting.
Spruce Biosciences, Inc. ownership disclosure: a group of Citadel-related reporting persons jointly report beneficial ownership positions in the issuer's Common Stock. The filing states Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may beneficially own 69,999 shares, and Kenneth Griffin may beneficially own 70,065 shares.
The filing cites 1,372,278 Shares outstanding as of March 24, 2026 and reports the listed holdings represent 5.1% of the class for the primary holders named. Shared voting and dispositive power is reported for those positions.
Spruce Biosciences (SPRB) ownership update: Alyeska Investment Group, L.P. and related filers report beneficial ownership of 61,670 shares of common stock, equal to 4.49% of the class as of March 31, 2026. The holding comprises 21,671 common shares, 9,999 shares issuable upon exercise of warrants, and 30,000 shares acquired in a private placement. The filing cites 1,372,043 shares outstanding per a Form 424B5 dated March 9, 2026. Alyeska Investment Group, L.P. discloses shared voting and dispositive power for the 61,670 shares, and Anand Parekh is identified as CEO of Alyeska Investment Group, L.P.; he disclaims beneficial ownership of certain shares held by Alyeska Master Fund, L.P.
Spruce Biosciences ownership update: Squadron Master Fund LP, Squadron Capital Management, LLC and principals Matthew Sesterhenn and William Blank each report beneficial ownership of 12,200 shares of common stock, representing 0.9% of the class. The filings state these shares reflect shared voting and dispositive power, with no sole voting or dispositive power. The ownership percentage is based on 1,372,043 shares outstanding as of March 3, 2026. The statement includes an express disclaimer of beneficial ownership under Rule 13d-4. The amendment is signed by reporting persons on 05/15/2026.
Spruce Biosciences, Inc. (Common Stock, CUSIP 85209E208) is reported as being beneficially owned in part by Wellington Management entities. The filing shows a 3.56% beneficial ownership position represented by shared voting power of 34,769 shares and shared dispositive power of 48,796. The Schedule 13G/A states these securities are owned of record by clients of Wellington Investment Advisers and lists the chain of parent and affiliate entities. The filing was signed by a compliance manager on 05/15/2026.